Molecular Medicine

, Volume 13, Issue 7–8, pp 443–451 | Cite as

Potential of Diallyl Sulfide Bearing pH-Sensitive Liposomes in Chemoprevention Against DMBA-Induced Skin Papilloma

  • Arif Khan
  • Yogeshwer Shukla
  • Neetu Kalra
  • Maroof Alam
  • Manzoor Gatoo Ahmad
  • Seema Rashid Hakim
  • Mohammad Owais


Diallyl sulfide (DAS), an active component of garlic, possesses strong anti-neoplastic properties against various forms of cancer. In the present study, we have evaluated chemo-preventive effects of liposomized DAS (conventional egg PC and pH-sensitive liposomes) against DMBA-induced skin papilloma. Various liposome-based novel formulations of DAS (250 µg/mouse) were applied topically, after one hour of exposure to DMBA (52 µg/mouse/dose), to the animals. The animals were treated thrice weekly for the total period of 12 weeks. The efficacy of the various liposomal formulations of DAS was evaluated on the basis of parameters such as incidence of tumorogenesis and total numbers and sizes of induced tumor nodules. The liposomized DAS formulations also were assessed for their effect on the expression of p53wt, p53mut, and p21/Waf1. The results of the present study showed that liposomized DAS could effectively delay the onset of tumorogenesis and reduce the cumulative numbers and sizes of tumor papillomas in treated mice. Treatment of DMBA-exposed animals with the liposomal formulation of DAS ensued in up-regulation of p53wt and p21/Waf1, while levels of p53mut expression reduced down. The promising chemo-preventive nature of liposomal DAS may form the basis for establishing effective means of controlling various forms of cancer, including skin papilloma.



We are thankful to our Coordinator Professor M Saleemuddin for allowing us to avail ourselves of the institute’s facilities. We are also thankful to Dr. C M Gupta, Director ITRC, Lucknow for providing access to all the facilities in the institute. Arif Khan acknowledges ICMR for Senior Research Fellowship.


  1. 1.
    Block E. (1985) The chemistry of garlic and onions. Sci. Am. 252:114–9.CrossRefGoogle Scholar
  2. 2.
    Agarwal KC. (1996) Therapeutic actions of garlic constituents. Med. Res. Rev. 16:111–24.CrossRefGoogle Scholar
  3. 3.
    Arora A, Kalra N, Shukla Y. (2006) Regulation of p21/ras protein expression by diallyl sulfide in DMBA induced neoplastic changes in mouse skin. Cancer Lett. 242:28–36.CrossRefGoogle Scholar
  4. 4.
    Prasad S, Kalra N, Shukla Y. (2006) Modulatory effects of diallyl sulfide against testosterone-induced oxidative stress in Swiss albino mice. Asian J. Androl. 8:719–23.CrossRefGoogle Scholar
  5. 5.
    Haber-Mignard D, Suschetet M, Berges R, Astorg P, Siess MH. (1996) Inhibition of aflatoxin B1 and N-nitrosodiethylamine induced liver preneoplastic foci in rats fed naturally occurring allyl sulfides. Nutr. Cancer. 25:61–70.CrossRefGoogle Scholar
  6. 6.
    Wargovich MJ, Imada O, Stephens LC. (1992) Initiation and post-initiation chemo-preventive effects of diallyl sulfide in esophageal carcinogenesis. Cancer Lett. 64:39–42.CrossRefGoogle Scholar
  7. 7.
    Wargovich MJ, Woods C, Eng VW, Stephens LC, Gray K. (1988) Chemoprevention of N-nitrosomethylbenzylamine-induced esophageal cancer in rats by the naturally occurring thioether, diallyl sulfide. Cancer Res. 48:6872–5.PubMedGoogle Scholar
  8. 8.
    Sparnins VL, Barany G, Watterberg LW. (1988) Effects of organosulphur compounds from garlic and onions on benzo (a) pyrene induced neoplasia and glutathione S-transferase activity in the mouse. Carcinogenesis. 9:131–4.CrossRefGoogle Scholar
  9. 9.
    Arora A, Siddiqui IA, Shukla Y. (2004) Modulation of p53 in 7,12-dimethylbenz [a] anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Mol. Cancer Ther. 3:1459–66.PubMedGoogle Scholar
  10. 10.
    Singh A, Shukla Y. (1999) Antitumor activity of diallyl sulfide in two stage mouse skin model of carcinogenesis. Biomed. Environ. Sci. 11:258–63.Google Scholar
  11. 11.
    Wargovich MJ. (1987) Diallyl sulfide, a flavor component of garlic (Allium sativum) inhibits dimethylhydrazine induced colon cancer. Carcinogenesis 8:487–9.CrossRefGoogle Scholar
  12. 12.
    Shukla Y, Arora A, Taneja P. (2003) Antigenotoxic potential of certain dietary constituents. Teratog. Carcinog. Mutagen 1:323–35.CrossRefGoogle Scholar
  13. 13.
    Smith TJ, Yang CS. (2000) Effect of organosulfur compounds from garlic and cruciferous vegetables on drug metabolism enzymes. Drug Metabol. Drug Interact. 17:23–49.CrossRefGoogle Scholar
  14. 14.
    Yang CS, Chhabra SK, Hong JY, Smith TJ. (2001) Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J. Nutr. 131:1041–57.CrossRefGoogle Scholar
  15. 15.
    Guyonnet D, Siess MH, Le Bon AM, Suschetet M. (1999) Modulation of phase II enzymes by organosulfur compounds from Allium vegetables in rat tissues. Toxicol. Appl. Pharmacol 154:50–8.CrossRefGoogle Scholar
  16. 16.
    Spiclin P, Homar M, Zupancic-Valant, Gasperlin M. (2003) Sodium ascorbyl phosphate in topical microemulsions. Int. Pharm. 256:65–73.CrossRefGoogle Scholar
  17. 17.
    Jia-You Fang, Tsong-Long Hwang, Yen-Ling Huanga, Chia-Lang Fang. (2006) Enhancement of the transdermal delivery of catechins by liposomes incorporating anionic surfactants and ethanol. Int. J. Pharm. 310:131–8.CrossRefGoogle Scholar
  18. 18.
    Muller RH, Radtke M, Wissing SA. (2002) Solid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54:131–55.CrossRefGoogle Scholar
  19. 19.
    Betz G, Aeppli A, Menshutina N, Leuenberger H. (2005) In vivo comparison of various liposome formulations for cosmetic application. Int. J. Pharm. 296:44–54.CrossRefGoogle Scholar
  20. 20.
    Kirjavainen M, Urtti A, Valjakka-Koskela R, Kiesvaara J, Mönkkönen J. (1999) Liposome-skin interactions and their effects on the skin permeation of drugs. Eur. J. Pharm. Sci. 7:279–86.CrossRefGoogle Scholar
  21. 21.
    Maestrelli F, Gonzalez-Rodriguez ML, Rasco AM, Mura P. (2005) Preparation and characterization of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery. Int. J. Pharm. 298:55–67.CrossRefGoogle Scholar
  22. 22.
    Cevc G. (1996) Transferosomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 13:257–388.CrossRefGoogle Scholar
  23. 23.
    Sharma A, Straubinger RM. (1994) Novel taxol formulations: Preparation and characterization of taxol-containing liposomes. Pharm. Res. 11:889–96.CrossRefGoogle Scholar
  24. 24.
    Skalko N, Peschka R, Atenschmidt U, Lung A, Schubert R. (1998) pH-sensitive liposomes for receptor-mediated delivery to chicken hepatoma (LMH) cells. FERS. 434:351–6.Google Scholar
  25. 25.
    Bhatia A, Kumar R, Katare OP. (2004) Tamoxifen in topical liposomes: development, characterization andin-vitro evaluation. J. Pharm. Pharm. Sci. 7:252–9.PubMedGoogle Scholar
  26. 26.
    Drummond DC, Meyer OM, Hong K, Kirpotin D, Papahadjopoulos D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51:691–743.PubMedGoogle Scholar
  27. 27.
    Guerin MR. (1978) Energy sources of polycyclic aromatic hydrocarbons. In: Gelboin HV, Tso POP, editors. Polycyclic hydrocarbons in cancers. vol 1, part I. New York: Academic Press. p. 3–42.Google Scholar
  28. 28.
    Dipple A, Mosschel RC, Bigger CAH. (1984) Polynuclear aromatic carcinogens. In: Charles E. Searle, editor. Chemical Carcinogens, vol 1. ACS Monograph 182. Washington, DC: American Chemical Society. p. 41–126.Google Scholar
  29. 29.
    Harasym TO, Cullis PR, Bally MB. (1997) Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother. Pharmacol. 40:309–17.CrossRefGoogle Scholar
  30. 30.
    Singleton WS, Gray MS and Brown ML. (1965) A method for adsorbent fractionation of cottonseed oil for experimental intravenous fat emulsions. J. Am. Oil Chem. Soc. 42:53–6.CrossRefGoogle Scholar
  31. 31.
    Owais M, Krishnakumar B, Jain RK, Bachhawat BK, C.M. Gupta. (1993) Tuftsin bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Lett. 326:56–8.CrossRefGoogle Scholar
  32. 32.
    Khan MA, Syed FM, Nasti HT, Saima Dagger K, Haq W, Shehbaz A, Owais M. Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B. J Drug Target 2003;11(2):93–9.CrossRefGoogle Scholar
  33. 33.
    Serpi R, Piispala J, Jarvilehto M, Vahakangas K. (1999) Thapsigargin has similar effect on p53 protein response to benzo(a)pyrene DNA adducts as TPA in mouse skin. Carcinogenesis. 20:1755–60.CrossRefGoogle Scholar
  34. 34.
    Towbin H, Staehelin T, Gordon J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U. S. A. 76:4350–4.CrossRefGoogle Scholar
  35. 35.
    Lowry OH, Rosenbrough NK, Farr AL, Randall RJ. (1951) Protein measurement with folin phenol reagent. J. Biol. Chem. 193:265–75.Google Scholar
  36. 36.
    Pinto JT, Rivlin RS. (2001) Antiproliferative effects of Allium derivatives from garlic. J. Nutr. 131:1058–60.CrossRefGoogle Scholar
  37. 37.
    Singh A, Shukla Y. (1998) Antitumor activity of diallyl sulfide on polycyclic aromatic hydrocarbon induced mouse skin carcinogenesis. Cancer Lett. 131:209–14.CrossRefGoogle Scholar
  38. 38.
    Fang JY, Hung CF, Hwang TL, Huang YL. (2005) Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J. Drug Target. 13:19–27.CrossRefGoogle Scholar
  39. 39.
    Dayan N, Touitou E. (2000) Carriers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposomes. Biomaterials. 21:1879–85.CrossRefGoogle Scholar
  40. 40.
    El Maghraby GMM, Williams AC, Barry BW. (2001) Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in vitro. J. Pharm. Pharmacol. 53:1069–77.CrossRefGoogle Scholar
  41. 41.
    Sergio Simoes, Vladimir Slepushkin, Nejat Duzgunes, Maria C. Pedroso de Lima. (2001) On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochimica et Biophysica Acta 1515:23–37.CrossRefGoogle Scholar
  42. 42.
    Yatvin MB, Kruetz W, Horwitz BA, Shinitzky M. (1980) pH-sensitive liposomes: possible clinical implications. Science. 210:1253–5.CrossRefGoogle Scholar
  43. 43.
    Huang SK et al. (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52:6774–81.PubMedGoogle Scholar
  44. 44.
    Dellian M, Helmlinger G, Yuan F, Jain RK. (1996) Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. Br. J. Cancer. 74:1206–15.CrossRefGoogle Scholar
  45. 45.
    Helmlinger G, Yuan F, Dellian M, Jain RK. (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nature Med. 3:177–82.CrossRefGoogle Scholar
  46. 46.
    Jenski LJ, Zerouga M, Stillwell W. (1995) Omega-3 fatty acid-containing liposomes in cancer therapy. Experimental Biology and Medicine 210:227–233.CrossRefGoogle Scholar
  47. 47.
    Hossain Z, Konishi M, Hosokawa M, Takahashi K. (2006) Effect of polyunsaturated fatty acid-enriched phosphatidylcholine and phosphatidylserine on butyrate-induced growth inhibition, differentiation and apoptosis in Caco-2 cells. Cell Biochem. Funct. 24:159–65.CrossRefGoogle Scholar
  48. 48.
    Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. (1998) The p53 network. J. Biol. Chem. 273:1–4.CrossRefGoogle Scholar
  49. 49.
    Mowat MR. (1998) p53 in tumor progression: life, death and everything. Adv. Cancer Res. 74:25–48.CrossRefGoogle Scholar
  50. 50.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991) p53 mutations in human cancers. Science. 253:49–53.CrossRefGoogle Scholar
  51. 51.
    Vousden KH, Lu X. (2002) Live or let die: the cell’s response to p53. Nat. Rev. Cancer 2:594–604.PubMedGoogle Scholar
  52. 52.
    Stommel JM et al. (1999) Aleucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1660–72.CrossRefGoogle Scholar
  53. 53.
    Lane DP. (1992) p53, guardian of the genome.- Nature. 358:15–6.CrossRefGoogle Scholar
  54. 54.
    Sengupta S, Vonesch JL, Waltzinger C, Zheng H, Wasylyck B. (2000) Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J. 19:6051–64.CrossRefGoogle Scholar
  55. 55.
    Lu W et al. (2000) Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene. 19:232–40.CrossRefGoogle Scholar
  56. 56.
    Burns PA et al. (1991) Loss of heterozygosity and mutational alterations of the p53 gene in skin tumors of interspecific hybrid mice. Oncogene. 6:2363–9.PubMedGoogle Scholar
  57. 57.
    el-Deiry WS et al. (1994) WAFI/CIPI is induced in p53 mediated G1 arrest and apoptosis. Cancer Res. 54:1169–74.PubMedGoogle Scholar
  58. 58.
    Schwartz D, Goldfinger N, Kam Z, Rotter V. p53 controls low DNA damage-dependent premeiotic checkpiont and facilitates DNA repair during spermatogenesis. Cell Growth Differ. 1999; 10(10):665–75.PubMedGoogle Scholar
  59. 59.
    Schwartz J, Shklar G, Trickler D. (1993) p53 in the anticancer mechanism of vitamin E. Eur. J. Cancer B. Oral Oncol. 29B:313–8.CrossRefGoogle Scholar
  60. 60.
    Yechiel E, Coste R. (2005) From Ancient Potions To Modern Lotions: A Technology Overview and Introduction to Topical Delivery Systems. Delivery System Handbook for Personal Care and Cosmetic Products: Technology, Applications and Formulations. Noyes Publications. Ed. M. R.Google Scholar
  61. 61.
    Padamwar MN, Pokharkar VB. (2006) Development of vitamin loaded topical liposomal formulation using factorial design approach: Drug deposition and stability. Int. J. Pharm. 320:37–44.CrossRefGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2007

Authors and Affiliations

  • Arif Khan
    • 1
  • Yogeshwer Shukla
    • 2
  • Neetu Kalra
    • 2
  • Maroof Alam
    • 1
  • Manzoor Gatoo Ahmad
    • 3
  • Seema Rashid Hakim
    • 3
  • Mohammad Owais
    • 1
  1. 1.Interdisciplinary Biotechnology UnitAligarh Muslim UniversityAligarhIndia
  2. 2.Environmental Carcinogenesis DivisionIndustrial Toxicology Research CenterLucknowIndia
  3. 3.J. N. Medical CollegeAligarh Muslim UniversityAligarhIndia

Personalised recommendations